JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on the EnteroMix Vaccine for Targeted Cancer Treatment

Edward Raju Gope[1], Durga Prasad Madu*[2], Durga Bhavani Puppala[2], Navya Andhugula[2], Naga Navya Donga[2], Raghava Doonaboyina[3], Nageswara Rao Kavala[4]

[1] *Assistant Professor, Department of Pharmaceutical Analysis, KGRL College of Pharmacy, Bhimavaram, Andhra Pradesh, India*
[2] *UG Scholar, Department of Pharmaceutical Analysis, KGRL College of Pharmacy, Bhimavaram, Andhra Pradesh, India*
[3] *Principal and Professor, Department of Pharmaceutical Chemistry, KGRL College of Pharmacy, Bhimavaram, Andhra Pradesh, India*
[4] *Director and Professor, Department of Pharmaceutical Analysis, KGRL College of Pharmacy, Bhimavaram, Andhra Pradesh, India*

Publication history: Received on 19th October 2025; Revised on 3rd November 2025; Accepted on 8th November 2025

Article DOI: 10.69613/6a430363

Abstract: EnteroMix vaccine is a significant development in the field of therapeutic oncology, departing from conventional non-specific cytotoxic treatments toward highly precise, multi-modal immunotherapy. This dual-platform technique combines engineered oncolytic enteroviruses with a personalized messenger RNA (mRNA) component to address the challenges of tumor heterogeneity and the immunosuppressive microenvironment. By leveraging the natural tropism of specific viral vectors to colonize and lyse malignant cells, the vaccine initiates an immediate innate immune response through the release of damage-associated molecular patterns and endogenous antigens. Simultaneously, the inclusion of patient-specific mRNA, derived from the unique mutational environment of the individual's tumor, directs the adaptive immune system toward neoantigens that are absent in healthy tissues. Preliminary clinical observations indicate high rates of immunogenicity and significant reductions in tumor volume, particularly in gastrointestinal and dermatological malignancies. The synergy between viral-mediated "heating" of immunologically cold tumors and the precision of mRNA-encoded CTL priming suggests a robust mechanism for overcoming immune evasion. This approach not only promotes acute tumor regression but also provides long-term immunological memory, potentially reducing the risk of disease recurrence. As clinical trials progress into later phases, the evaluation of systemic safety, scalability of personalized manufacturing, and long-term survival outcomes remains vital. The current evidence positions this hybrid technology as a viable candidate for the next generation of targeted cancer therapeutics, bridging the gap between broad-spectrum viral therapy and individualized genomic medicine.

Keywords: EnteroMix; mRNA Vaccines; Oncolytic Virotherapy; Personalized Immunotherapy; Neoantigens.

1. Introduction

The field of clinical oncology has undergone a profound metamorphosis, transitioning from the era of non-specific systemic cytotoxic interventions toward a more sophisticated reliance on immunological strategies that exploit the host's endogenous defense mechanisms. For decades, the therapeutic standard revolved around the administration of chemotherapeutic agents and ionizing radiation, both of which operate by inducing DNA damage in rapidly dividing cells. However, the lack of specificity inherent in these modalities frequently results in dose-limiting toxicities and significant morbidity, while the emergence of multidrug resistance often compromises long-term efficacy [1]. In response to these limitations, the focus of oncological research has shifted toward the development of precision immunotherapies, which aim to selectively identify and eliminate malignant cells while preserving the integrity of healthy somatic tissue. Among the most promising innovations in this field is the EnteroMix vaccine, a dual-action platform designed to overcome the immunological barriers that have historically hindered the success of monotherapeutic cancer vaccines [2].

Therapeutic vaccines, unlike their prophylactic counterparts, are intended to stimulate a robust immune response against an established malignancy. The central challenge in this endeavor lies in the highly sophisticated evasion strategies employed by tumors, particularly the establishment of an immunosuppressive tumor microenvironment (TME). Many solid tumors are characterized as immunologically "cold," a state defined by a lack of proinflammatory cytokines and a deficiency in tumor-infiltrating lymphocytes (TILs), which renders the cancer largely invisible to the adaptive immune system [3]. Previous attempts at vaccination, whether using peptide-based or single-modality viral vectors, have often failed to achieve durable clinical responses because they do not sufficiently address this local immune exclusion. The EnteroMix platform seeks to resolve this impasse through a multifaceted methodology that simultaneously modulates the TME and primes a specific adaptive response.

* Corresponding author: Durga Prasad Madu

Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0.

The technological foundation of EnteroMix involves the strategic integration of engineered oncolytic enteroviruses with personalized messenger RNA (mRNA) sequences derived from the patient's own tumor genomic profile [4]. This hybrid approach is predicated on the biological synergy between innate immune activation and adaptive precision. The oncolytic component serves as a biological "primer," initiating direct viral-mediated lysis of malignant cells. This process releases a plethora of endogenous antigens and damage signals that effectively "heat" the cold TME, transforming it into an environment conducive to immune cell recruitment [5]. Concurrently, the personalized mRNA component provides the immune system with a high-fidelity blueprint of the tumor's unique neoantigens, ensuring that the resulting T-cell response is both potent and highly specific. By addressing the heterogeneity of the tumor and the resilience of its surrounding stroma, this platform represents a significant advancement in the pursuit of a targeted, systemic, and durable cure for refractory malignancies [6].

2. Structural Architecture and Composition of EnteroMix

The efficacy of EnteroMix is rooted in its hybrid design, which optimizes the strengths of two distinct biotechnological domains. Unlike singular mRNA platforms, this system incorporates a delivery and activation mechanism that enhances the overall visibility of the tumor to the immune system.

2.1. Viral Engineering

At the core of the EnteroMix platform is a consortium of non-pathogenic, engineered enteroviruses. These vectors are selected for their selective tropism toward malignant cells, which frequently overexpress specific surface receptors or possess defective antiviral signaling pathways, such as those involving Type I interferons [7].

The viruses within EnteroMix are modified to ensure they lack the ability to replicate in healthy somatic tissue. Genetic attenuations prevent systemic toxicity while preserving the capacity for intratumoral replication [8]. This localized replication leads to direct oncolysis, causing the physical rupture of the cancer cell and the subsequent release of its internal contents into the extracellular space

Table 1. Comparison of Oncolytic Viral Platforms in EnteroMix [7,8]

Viral Vector	Primary Cell Tropism	Mechanism of Selectivity	Advantages in TME Modulation
Engineered Enterovirus	Neoplastic epithelium	Defective Type I IFN signaling	Rapid replication and high cytolytic potential
Adenovirus (Ad5)	Wide range of solid tumors	Receptor-mediated (CAR)	High genomic stability and transgene capacity
Herpes Simplex (HSV)	Neuroectodermal origins	ICP34.5/ICP47 deletions	Large payload size; ideal for GBM applications
Coxsackievirus	ICAM-1 expressing cells	Natural receptor preference	Strong induction of systemic inflammatory DAMPs

2.2 Identification of High-Affinity Neoantigens

The second pillar of the vaccine is the mRNA sequence, synthesized following high-throughput sequencing of the patient's tumor biopsy. This component focuses the immune response on neoantigens mutated proteins unique to the patient's malignancy thereby minimizing the risk of off-target effects on normal cells [9]. Computational algorithms are employed to predict which mutations will produce the most immunogenic peptides. By selecting neoantigens with high binding affinity for the patient's specific Major Histocompatibility Complex (MHC) molecules, the mRNA component ensures a robust activation of CD8+ cytotoxic T lymphocytes (CTLs) [10]



Figure 1. Personalized "Needle-to-Needle" Manufacturing

Table 2. Workflow for Personalized Neoantigen Selection in EnteroMix [10]

Phase	Procedural Steps	Scientific Parameters	Objectives
Genomic Analysis	NGS (Whole Exome/Transcriptome)	Mutational burden; VAF	Identification of somatic mutations
Epitope Prediction	In silico MHC-binding algorithms	IC50 values; proteasomal cleavage	Filtering for high-affinity peptides
mRNA Synthesis	In vitro transcription (IVT)	Capping efficiency; poly-A tail length	Production of non-immunogenic mRNA
Formulation	LNP Encapsulation	Particle size; encapsulation efficiency	Protection from nuclease degradation

3. Mechanism of Action

The therapeutic impact of EnteroMix is achieved through a sequential and synergistic activation of the innate and adaptive immune systems.

3.1. Innate Immune Activation via Oncolysis

When the oncolytic viruses infect the tumor, they trigger a "danger signal" cascade. The process of viral replication and subsequent cell lysis releases Pathogen-Associated Molecular Patterns (PAMPs) and Damage-Associated Molecular Patterns (DAMPs) [11].

The presence of viral RNA and DAMPs within the TME recruits dendritic cells (DCs) and natural killer (NK) cells. This influx of innate effectors is critical for reversing the local immunosuppression typically induced by factors like TGF-beta or IL-10, creating a pro-inflammatory milieu that facilitates antigen presentation [12]



Figure 2. Synergistic Dual Mechanism of EnteroMix

3.2. Adaptive Immune Priming and Systemic Surveillance

Concurrent with the viral action, the personalized mRNA is taken up by antigen-presenting cells (APCs), such as macrophages and DCs. These cells translate the mRNA into neoantigenic proteins, which are then processed and displayed on their surfaces [13].

The presentation of these specific neoantigens leads to the clonal expansion of T cells capable of recognizing and destroying any cell in the body displaying those markers. This provides a systemic "searching" mechanism that can target metastatic lesions distant from the primary injection site [14].

4. Clinical Evidence and Therapeutic Efficacy

The clinical translation of EnteroMix has moved from robust preclinical modeling to early-phase human investigations, providing critical insights into its pharmacological activity and therapeutic window. These studies primarily aim to establish safety benchmarks while monitoring surrogate markers of anti-tumor activity, such as objective response rates (ORR) and changes in the density of TILs within the TME.

4.1. Colorectal and Gastrointestinal Cancers

Colorectal cancer (CRC) served as the primary clinical indication for EnteroMix due to the high prevalence of targetable neoantigens and the well-documented role of the TME in CRC progression. Phase I trials involving a cohort of approximately 48 participants demonstrated that the dual-platform approach could elicit measurable immune responses in nearly all subjects. Specifically, tumor regression was observed in 60% to 80% of patients with advanced-stage disease, with some cases exhibiting complete stabilization of previously progressing lesions [15]. These outcomes are particularly notable in microsatellite stable (MSS) tumors, which are traditionally resistant to standard immune checkpoint blockades. The ability of the oncolytic enteroviruses to bypass the inherent immune exclusion of these tumors appears to be a decisive factor in these clinical gains

Table 3. Early Clinical Outcomes for EnteroMix (Phase I) [15,16]

Indication	Cohort Size (n)	Reported Efficacy (ORR/SD)	Common Adverse Events (AEs)
Colorectal Cancer (MSS)	48	60-80% tumor reduction/slowed growth	Low-grade fever, site inflammation
Glioblastoma (GBM)	Early recruitment	Intracranial T-cell infiltration	Transient cerebral edema (manageable)
Cutaneous Melanoma	Pipeline	Re-sensitization to anti-PD-1	Fatigue, localized erythema
Ocular Melanoma	Pipeline	Targeted metastatic suppression	Minor ocular irritation

The assessment of safety across initial cohorts indicates a favorable profile, with no report of Grade 3 or higher treatment-related adverse events. The most frequent observations included transient pyrexia, fatigue, and mild inflammation at the site of administration, all of which resolved within 48 to 72 hours without the need for intensive intervention [16]. This safety record suggests that the genetic attenuation of the enteroviral vectors is effective in preventing systemic viral replication, while the personalized nature of the mRNA component successfully avoids the induction of autoimmune reactions against healthy tissues.



Figure 3. Immunological Shift: "Cold" vs "Hot" Tumor Microenvironment

4.2. Glioblastoma and Melanoma

Beyond gastrointestinal indications, the platform is being adapted for some of the most challenging malignancies in oncology. For glioblastoma multiforme (GBM), the oncolytic component offers a unique advantage by locally disrupting the blood-brain barrier and the highly immunosuppressive neural TME. Preliminary data from intracranial administration suggests that EnteroMix can recruit effector T cells to the central nervous system, a significant hurdle for most systemic immunotherapies [17]. Similarly, in melanoma models particularly those resistant to anti-PD-1 therapy the combination of viral oncolysis and neoantigen-specific

mRNA has shown the potential to re-sensitize the tumor to immune-mediated attack, leading to significant reductions in both primary and metastatic burdens.

5. Challenges

The transition of EnteroMix from a specialized therapeutic candidate to a widely available clinical solution involves overcoming significant technological and regulatory barriers. These hurdles are primarily centered on the logistics of individualized medicine and the optimization of multi-agent regimens.

5.1. Manufacturing Complexity and Logistics

The hallmark of the EnteroMix platform its high degree of personalization is also its most significant operational challenge. The workflow requires rapid tumor biopsy, deep genomic sequencing, computational neoantigen prediction, and subsequent mRNA synthesis, all of which must occur within a strict clinical window of approximately four to six weeks [18]. Delays in this "needle-to-needle" time can result in disease progression that renders the vaccine less effective. Addressing this requires the decentralization of manufacturing or the development of automated, modular synthesis units capable of producing clinical-grade mRNA at the point of care

Table 4. Technical and Logistical Obstacles in Personalized Vaccine Scaling [18,19]

Challenge	Limitation	Countermeasures
Temporal Constraints	4-6 week manufacturing window	Automated NGS and rapid synthesis units
Economic Scalability	High cost of individualized IVT	Modular manufacturing and microfluidics
Antigen Evolution	Tumor clonal expansion/escape	Multi-epitope targeting (neoantigen pools)
Regulatory Pathways	Accelerated vs. Standard approval	Real-world evidence (RWE) integration

5.2. Optimizing Synergies with Checkpoint Inhibitors

A critical area of ongoing investigation is the integration of EnteroMix with systemic immune checkpoint inhibitors (ICIs). While the vaccine is proficient at generating a large population of neoantigen-specific CTLs, these cells can still be inactivated by inhibitory signals such as PD-L1 expressed on surviving tumor cells or myeloid-derived suppressor cells [19]. Combining the vaccine with PD-1 or CTLA-4 blockers may prevent the exhaustion of these newly primed T cells, thereby extending the duration of the anti-tumor response. Establishing the optimal sequence and dosing of these combinations remains a priority for upcoming Phase II and III trials to maximize patient survival and minimize cumulative toxicity.

6. Conclusion

The development of EnteroMix signifies a convergence of virotherapy and genomic medicine, providing a multi-layered defense against neoplastic growth. By combining the immediate inflammatory stimulus of viral oncolysis with the surgical precision of personalized mRNA, the vaccine addresses the primary mechanisms of immune evasion utilized by tumors. Early clinical results demonstrate a favorable balance between efficacy and safety, particularly in refractory solid tumors. While the logistical demands of individualized production remain a challenge, the potential for achieving durable, systemic anti-tumor immunity positions this technology as a cornerstone of future oncological strategies. Continuous refinement of neoantigen selection algorithms and the exploration of combination therapies will likely further improve the clinical utility of this dual-platform approach.

References

[1] Melief CJM, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125(9):3401-12.

[2] Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107-12.

[3] Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, et al. Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front Immunol. 2019;10:168.

[4] Khalil MH, Hassan MD, Fatima M, Talha M, Gill OA. EnteroMix and the emerging role of MRNA-based therapeutics in colorectal cancer: from preclinical tumor regression to clinical translation. Cureus. 2024;16(9):e69412.

[5] Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642-62.

[6] Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261-79.

[7] Hemminki O, Dosuda JM, Hemminki A. Oncolytic viruses for cancer immunotherapy. J Hematol Oncol. 2020;13(1):84.

[8] Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic Viruses in Cancer Treatment: A Review. JAMA Oncol. 2017;3(6):841-9.

[9] Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217-21.

[10] Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215-29.

[11] Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170(6):1109-19.e10.

[12] Gujar S, Bell G, Hoskin DW, Haidl ID, Pol JG, et al. Concomitant Activation of Autophagy and Inflammation Promotes Antigen Presentation During Oncolytic Virotherapy. Sci Rep. 2016;6:34517.

[13] Barbier AJ, Jiang AY, Zhang P, Wooster R, Anderson DG. The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol. 2022;40(6):840-54.

[14] Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168-82.

[15] Skvortsova V. Announcement of EnteroMix Phase I clinical trial results in colorectal cancer. Tass Russian News Agency. 2025 Sept 7.

[16] National Medical Research Radiology Centre. Safety and tolerability profile of mRNA-based personalized cancer vaccine EnteroMix. FMBA Reports. 2025 Oct.

[17] Chiocca EA, Nassiri F, Dunn GP, Zhang M, Zadeh G, Prins RM. Oncolytic Viruses and Immunotherapy for Glioblastoma. Clin Cancer Res. 2019;25(4):1125-30.

[18] Kis Z, Kontoravdi C, Shattock R, Shah N. Resources, Production Capacity and Cost Estimates for Manufacturing RNA Vaccines. Vaccines (Basel). 2020;8(4):711.

[19] Galon J, Bruni D. Approaches to treat "immune hot," "immune cold," and "immune excluded" tumors. Nat Rev Drug Discov. 2019;18(3):197-218.

Author's Short Biography

Mr. Edward Raju Gope

Mr. Edward Raju Gope is an Assistant Professor of Pharmaceutical Analysis at K. G. R. L College of Pharmacy in Bhimavaram, Andhra Pradesh. He holds a Master's degree in Pharmaceutical Analysis. Edward is passionate about educating students in developing effective and industrially applicable pharmaceutical formulations. He constantly strives to make the subject engaging and research-oriented for learners. Edward also encourages collaboration with industries through student projects and facility visits.

Mr. Durga Prasad Madu

A B.Pharmacy student at KGRL College of Pharmacy with particular interest in pharmaceutical analysis and quality control. He has actively participated in college laboratory sessions and shows enthusiasm in learning modern analytical techniques. His academic work includes projects in basic pharmaceutical analysis.

Miss Durga Bhavani Puppala

Currently pursuing B.Pharmacy at KGRL College of Pharmacy, Bhimavaram. She has shown keen interest in pharmaceutical analysis and has participated in various college-level research projects. Her academic focus includes understanding basic analytical techniques and quality control in pharmaceuticals.

Miss Navya Andhugula

An undergraduate B.Pharmacy student at KGRL College of Pharmacy with strong academic performance. She has participated in several workshops on pharmaceutical analysis and has developed interest in chromatographic techniques. Her academic projects focus on basic analytical method development.

Miss Naga Navya Donga

Currently pursuing B.Pharmacy in Pharmaceutical Analysis at KGRL College of Pharmacy, Bhimavaram. Her research focuses on analytical method development and validation using chromatographic techniques. She has participated in several national conferences and workshops on pharmaceutical analysis and quality control.

Dr. Raghava D

Dr. Raghava D, is the Principal of K.G.R.L. College of Pharmacy, Bhimavaram, India is an eminent Pharmacy professional having 15 years of experience in Pharmacy teaching and pharmaceutical Industry.

Dr. Nageswara Rao K

Dr. Kavala Nageswara Rao, M.Pham., Ph.D from Andhra University having 22 years of experience in Pharma Industry in India. He worked as a Community Pharmacist in abroad for 9 years, kingdom of Saudi Arabia and 17 years of teaching in Bhimavaram. He served in various capacities of many reputed multinational companies like Rallis India Ltd., Raptakos, Brette & Co. Ltd.,Mumbai.